Welcome to our dedicated page for Atara Biotherape SEC filings (Ticker: ATRA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Investors tracking Atara Biotherapeutics鈥� evolving T-cell pipeline know each 10-K line on R&D spend, every 8-K about trial outcomes, and all Form 4 insider trades can move the share price. Yet the documents stretch hundreds of pages and bury critical data in medical jargon. If you have ever searched 鈥淎tara Biotherapeutics SEC filings explained simply鈥� or asked where to find 鈥淎tara Biotherapeutics insider trading Form 4 transactions,鈥� Stock Titan already has the answers.
From the very first 10-Q earnings update to the latest shelf registration, our platform captures every submission the moment it hits EDGAR and channels it through our AI engine. You receive concise summaries that convert biotech terminology into plain English, real-time alerts for 鈥淎tara Biotherapeutics Form 4 insider transactions,鈥� and side-by-side views of sequential 鈥淎tara Biotherapeutics quarterly earnings report 10-Q filing鈥� trends. Need context on an 8-K headline? Click 鈥淎tara Biotherapeutics 8-K material events explained鈥� to read a 90-second recap instead of parsing legal prose.
Because Atara鈥檚 disclosures revolve around first-in-class T-cell therapies, our tools surface what matters most: clinical milestone timelines, collaboration revenue, cash runway, and manufacturing capacity hidden deep in MD&A. Quickly compare pay packages via the 鈥淎tara Biotherapeutics proxy statement executive compensation鈥� portal or explore the 鈥淎tara Biotherapeutics annual report 10-K simplified鈥� risk-factor heat map. Whether you鈥檙e screening 鈥淎tara Biotherapeutics executive stock transactions Form 4鈥� before earnings or pursuing 鈥淎tara Biotherapeutics earnings report filing analysis,鈥� Stock Titan transforms raw filings into clear, actionable insight鈥攕o you focus on decisions, not document archaeology.
Atara Biotherapeutics (ATRA) reported a pronounced change in its mid鈥�2025 financial position driven by transactions with Pierre Fabre and cost reductions. Total assets declined to $36.9 million at June 30, 2025 from $109.1 million at year鈥慹nd, and cash and cash equivalents were $16.9 million. Total liabilities fell to $71.9 million, and stockholders鈥� deficit improved to $(35.0) million.
Commercialization revenue for the six months ended June 30, 2025 was $115.7 million, reflecting recognition of deferred revenue tied to the transfer of manufacturing, inventory and related services to Pierre Fabre; deferred revenue declined from $95.1 million at year鈥慹nd to $1.6 million at June 30. Net income for the six months was $40.4 million versus a loss of $50.8 million a year earlier, producing basic earnings per share of $3.52 for the period. The company recorded restructuring charges of $11.3 million and a lease right鈥憃f鈥憉se impairment of $4.1 million. Management discloses substantial doubt about the company鈥檚 ability to continue as a going concern and plans to seek additional capital.
Atara Biotherapeutics reported that it announced financial results for the second quarter ended June 30, 2025 and furnished a press release as Exhibit 99.1 to its Form 8-K. The filing specifies the press release is being furnished (not "filed") and therefore is not subject to the liabilities of Sections 11 and 12(a)(2) of the Securities Act or deemed "filed" under Section 18 of the Exchange Act, and will not be incorporated by reference into other SEC filings unless expressly referenced. The Form lists the company ticker as ATRA and is signed by the Chief Accounting Officer.
FAQ
What is the current stock price of Atara Biotherape (ATRA)?
What is the market cap of Atara Biotherape (ATRA)?
